FDA
approval
· 2022-03-31
FDA Approved: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
Summary
The FDA approved a supplemental application for Teva’s generic fixed-dose combination emtricitabine and tenofovir disoproxil fumarate. This action authorizes th…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)